| Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma BA Walker, K Mavrommatis, CP Wardell, TC Ashby, M Bauer, FE Davies, ... Blood, The Journal of the American Society of Hematology 132 (6), 587-597, 2018 | 432 | 2018 |
| A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis BA Walker, K Mavrommatis, CP Wardell, TC Ashby, M Bauer, F Davies, ... Leukemia 33 (1), 159-170, 2019 | 429 | 2019 |
| Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing L Rasche, SS Chavan, OW Stephens, PH Patel, R Tytarenko, C Ashby, ... Nature communications 8 (1), 268, 2017 | 365 | 2017 |
| Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma N Weinhold, C Ashby, L Rasche, SS Chavan, C Stein, OW Stephens, ... Blood, The Journal of the American Society of Hematology 128 (13), 1735-1744, 2016 | 231 | 2016 |
| Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma L Rasche, D Alapat, M Kumar, G Gershner, J McDonald, CP Wardell, ... Leukemia 33 (7), 1713-1722, 2019 | 139 | 2019 |
| The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma EM Boyle, S Deshpande, R Tytarenko, C Ashby, Y Wang, MA Bauer, ... Nature communications 12 (1), 293, 2021 | 89 | 2021 |
| The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma S Thanendrarajan, E Tian, P Qu, P Mathur, C Schinke, F van Rhee, ... Haematologica 102 (9), e364, 2017 | 83 | 2017 |
| Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker SS Chavan, J He, R Tytarenko, S Deshpande, P Patel, M Bailey, CK Stein, ... Blood cancer journal 7 (2), e535-e535, 2017 | 74 | 2017 |
| Microhomology-mediated end joining drives complex rearrangements and overexpression of MYC and PVT1 in multiple myeloma A Mikulasova, C Ashby, RG Tytarenko, P Qu, A Rosenthal, JA Dent, ... Haematologica 105 (4), 1055, 2020 | 55 | 2020 |
| BRAF and DIS3 Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma EM Boyle, C Ashby, RG Tytarenko, S Deshpande, H Wang, Y Wang, ... Clinical Cancer Research 26 (10), 2422-2432, 2020 | 50 | 2020 |
| Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials SA Danziger, M McConnell, J Gockley, MH Young, A Rosenthal, ... PLoS Medicine 17 (11), e1003323, 2020 | 47 | 2020 |
| Usability survey of biomedical question answering systems MA Bauer, D Berleant Human genomics 6, 1-4, 2012 | 42 | 2012 |
| The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states L Rasche, C Schinke, F Maura, MA Bauer, C Ashby, S Deshpande, ... Nature communications 13 (1), 4517, 2022 | 33 | 2022 |
| Kinase domain activation through gene rearrangement in multiple myeloma GJ Morgan, J He, R Tytarenko, P Patel, OW Stephens, S Zhong, ... Leukemia 32 (11), 2435-2444, 2018 | 31 | 2018 |
| Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level C Schinke, AM Poos, M Bauer, L John, S Johnson, S Deshpande, ... Blood Advances 6 (22), 5873-5883, 2022 | 30 | 2022 |
| Towards the integration, annotation and association of historical microarray experiments with RNA-seq SS Chavan, MA Bauer, EA Peterson, CJ Heuck, DJ Johann BMC bioinformatics 14, 1-11, 2013 | 27 | 2013 |
| Chromothripsis as a pathogenic driver of multiple myeloma F Maura, EM Boyle, EH Rustad, C Ashby, D Kaminetzky, B Bruno, ... Seminars in cell & developmental biology 123, 115-123, 2022 | 25 | 2022 |
| The functional epigenetic landscape of aberrant gene expression in molecular subgroups of newly diagnosed multiple myeloma SR Choudhury, C Ashby, R Tytarenko, M Bauer, Y Wang, S Deshpande, ... Journal of hematology & oncology 13, 1-15, 2020 | 25 | 2020 |
| Differential RNA splicing as a potentially important driver mechanism in multiple myeloma MA Bauer, C Ashby, C Wardell, EM Boyle, M Ortiz, E Flynt, A Thakurta, ... Haematologica 106 (3), 736, 2021 | 24 | 2021 |
| The genomic landscape of plasma cells in systemic light chain amyloidosis EM Boyle, C Ashby, CP Wardell, D Rowczenio, S Sachchithanantham, ... Blood, The Journal of the American Society of Hematology 132 (26), 2775-2777, 2018 | 19 | 2018 |
Cody AshbyAssistant Professor, University of Arkansas for Medical Sciences在 uams.edu 的电子邮件经过验证
